DPP4 and Hypoglycemia: Data revealed that the DPP-4 inhibitor group had a lower incidence of hypoglycemia than did the glipizide group (551 participants, random RR 0.40, 95%CI 0.23 to 0.69; p = 0.0009; there was no heterogeneity (I2 = 0%; p = 0.42) (Figure 8B).